ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None2022202120202019 Date Title 20 September 2022 Change of Director's Interest Notice 12 September 2022 Change of Director's Interest Notice 31 August 2022 MSB Annual Financial Results and Operational Highlights 31 August 2022 Annual Financial Results Presentation 31 August 2022 Preliminary Final Report 30 August 2022 Mesoblast 2022 Full Year Financial Results Webcast 18 August 2022 Director Appointment 18 August 2022 Initial Director's Interest Notice 18 August 2022 Final Director's Interest Notice 16 August 2022 Ceasing to be a substantial holder - Tiga Trading Pty Ltd 16 August 2022 Ceasing to be a substantial holder from TEK 16 August 2022 Ceasing to be a substantial holder from TOP 16 August 2022 Change in substantial holding 12 August 2022 Cleansing Notice 12 August 2022 Appendix 2A 09 August 2022 Appendix 3B 09 August 2022 US$45 Million Private Placement to Major Shareholders 09 August 2022 Reinstatement to Quotation 08 August 2022 Voluntary Suspension 04 August 2022 Trading Halt 04 August 2022 Pause in Trading 29 July 2022 Quarterly Activities/Appendix 4C Cash Flow Report 19 July 2022 Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE 14 July 2022 Appendix 3H and Appendix 3Y 12 July 2022 Rexlemestrocel-L to be Highlighted on Heart Failure Panel 21 June 2022 Mesoblast CLBP Event with Key Opinion Leaders 21 June 2022 Chronic Low Back Pain KOL Event Presentation 14 June 2022 Litigation Update 09 June 2022 Mesoblast to Host KOL Event on Chronic Low Back Pain 01 June 2022 Third Quarter Results Presentation 01 June 2022 MSB Q3 Financial Results and Operational Highlights 01 June 2022 Third Quarter Financial Results on Form 6-K 31 May 2022 Mesoblast Q3 Financial Results Webcast 31 May 2022 Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients 30 May 2022 Ceasing to be a substantial holder 20 May 2022 Becoming a substantial holder 19 May 2022 Litigation Update 03 May 2022 Ceasing to be a substantial holder 02 May 2022 Ceasing to be a substantial holder 29 April 2022 Quarterly Activities/Appendix 4C Cash Flow Report 19 April 2022 Becoming a substantial holder 14 April 2022 Appendix 3G and Appendix 3H 06 April 2022 Company Secretary Appointment 29 March 2022 Becoming a substantial holder 28 March 2022 Initial Director's Interest Notice 24 March 2022 Director Appointment 04 March 2022 S&P DJI Announces March 2022 Quarterly Rebalance 25 February 2022 Final Director's Interest Notice 25 February 2022 MSB Q2 Financial Results and Operational Highlights 25 February 2022 Second Quarter Results Presentation 25 February 2022 Half Yearly Report and Accounts 24 February 2022 Mesoblast Q2 Financial Results Webcast 21 February 2022 Ulcerative Colitis & Crohns Results Presented at ECCO 02 February 2022 Mesoblast Appoints Dr Eric Rose as Chief Medical Officer 31 January 2022 Appendix 4C Quarterly Activity Report 25 January 2022 MSB Presents at Edison Group Global Healthcare Conference 18 January 2022 Cleansing Notice and Appendix 2A 18 January 2022 Proposed issue of securities - MSB 17 January 2022 Appendix 3G, Appendix 3H and Appendix 3Y 12 January 2022 36-Month Results of Phase 3 Trial in Chronic Low Back Pain 12 January 2022 Biotech Showcase 2022 Presentation 06 January 2022 Prospectus for Warrants Related to Oaktree Debt Refinance
